The G Allele of CaSR R990G Polymorphism Increases Susceptibility to Urolithiasis and Hypercalciuria: Evidences from a Comprehensive Meta-Analysis

Table 3

Summary OR and 95% CI of the CaSR polymorphisms and urolithiasis risk.

(a) A986S

		AS versus AA		SS versus AA		SS versus AA/AS			AS/SS versus AA
Total	9	0.97 (0.79–1.19)	0.261	1.04 (0.48–2.25)	0.060	1.08 (0.53–2.19)	0.099	10	0.94 (0.71–1.25)	0.031
Ethnicity
Asian	4	1.64 (1.04–2.59)	0.549	4.18 (0.84–20.86)	0.770	3.97 (0.80–19.76)	0.782	4	1.78 (1.13–2.80)	0.591
Caucasian	5	0.85 (0.67–1.07)	0.778	0.74 (0.31–1.80)	0.029	0.81 (0.35–1.85)	0.047	6	0.78 (0.62–0.99)	0.257
Subjects
PHPT and healthy	3	0.98 (0.48–1.41)	0.918	1.35 (0.60–3.02)	0.412	1.35 (0.61–3.00)	0.421	3	1.03 (0.73–1.45)	0.773
PHPT patients	3	0.70 (0.44–1.10)	0.690	0.38 (0.10–1.42)	0.221	0.44 (0.12–1.44)	0.248	3	0.62 (0.40–0.96)	0.351
Healthy population	3	1.10 (0.82–1.47)	0.038	1.95 (0.91–4.18)	0.667	2.07 (0.95–4.52)	0.512	4	1.13 (0.65–1.96)	0.009
SOC
PB	5	1.07 (0.84–1.36)	0.156	1.72 (0.97–3.05)	0.641	1.74 (0.99–3.06)	0.664	6	1.10 (0.77–1.57)	0.035
HB	4	0.74 (0.50–1.10)	0.809	0.40 (0.16–1.02)	0.330	0.44 (0.19–1.00)	0.376	4	0.67 (0.46–0.96)	0.442

(b) R990G

		RG versus RR		GG versus RR		GG versus RR/RG			RG/GG versus RR
Total	6	1.45 (0.90–2.34)	0.029	1.90 (0.49–7.30)	0.000	1.84 (0.53–6.43)	0.000	9	2.10 (1.23–3.58)	0.001
Ethnicity
Asian	3	1.27 (0.54–2.96)	0.059	0.63 (0.26–1.51)	0.213	0.65 (0.32–1.33)	0.246	3	1.26 (0.47–3.40)	0.017
Caucasian	3	1.74 (0.88–3.42)	0.063	7.01 (2.85–17.27)	0.745	6.73 (2.74–16.53)	0.717	6	2.71 (1.50–4.91)	0.044
Subjects
PHPT and healthy	2	1.11 (0.65–1.90)	0.223	1.07 (0.07–15.53)	0.105	1.07 (0.09–12.75)	0.123	3	1.45 (0.61–3.41)	0.014
PHPT patients	2	2.40 (0.28–20.65)	0.009	0.76 (0.30–1.96)	0.575	0.79 (0.35–1.81)	0.646	3	3.61 (0.55–23.84)	0.004
Healthy population	2	2.28 (0.50–10.45)	0.051	7.57 (3.00–19.11)	0.877	7.27 (2.89–18.31)	0.851	3	3.36 (1.00–11.28)	0.064
SOC
PB	4	1.31 (0.83–2.08)	0.123	2.87 (0.37–22.43)	0.000	2.83 (0.39–20.63)	0.000	5	1.64 (0.90–3.01)	0.013
HB	2	2.40 (0.28–20.65)	0.009	0.76 (0.30–1.96)	0.575	0.79 (0.35–1.81)	0.646	4	3.40 (0.97–11.85)	0.004

(c) Q1011E

		QE versus QQ		EE versus QQ		EE versus QQ/QE			QE/EE versus QQ
Total	4	1.59 (0.91–2.81)	0.201	2.20 (0.40–12.07)	0.863	2.14 (0.39–11.75)	0.859	4	1.59 (0.91–2.81)	0.201

Number of studies
^b value of test for heterogeneity
SOC: Source of controls, HB: hospital-based control group, and PB: population-based control group.